Free Trial
NASDAQ:MNPR

Monopar Therapeutics (MNPR) Stock Price, News & Analysis

$0.62
+0.01 (+1.64%)
(As of 05/23/2024 ET)
Today's Range
$0.60
$0.63
50-Day Range
$0.59
$0.79
52-Week Range
$0.27
$1.75
Volume
36,124 shs
Average Volume
3.43 million shs
Market Capitalization
$10.84 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$2.00

Monopar Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
222.6% Upside
$2.00 Price Target
Short Interest
Healthy
1.24% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.37) to ($0.35) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.35 out of 5 stars

Medical Sector

477th out of 915 stocks

Pharmaceutical Preparations Industry

202nd out of 399 stocks

MNPR stock logo

About Monopar Therapeutics Stock (NASDAQ:MNPR)

Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer. The company also engages in developing Camsirubicin, an analog of doxorubicin, which is in Phase 1b clinical trial for the treatment of advanced soft tissue sarcoma; MNPR-101, a urokinase plasminogen activator receptor targeted antibody for the treatment of various cancers; MNPR-101 RIT, a radioimmunotherapeutic based on MNPR-101 for the potential treatment of cancer and severe COVID-19; and MNPR-202, an analog of camsirubicin to treat doxorubicin-and camsirubicin-resistant cancers. Monopar Therapeutics Inc. has collaborations with the Grupo Español de Investigación en Sarcomas for the development of camsirubicin in patients with advanced soft tissue sarcoma; NorthStar Medical Radioisotopes, LLC to develop radio-immuno-therapeutics targeting severe COVID-19; and the Cancer Science Institute of Singapore to evaluate the activity of MNPR-202 and related analogs in various types of cancer. The company was founded in 2014 and is headquartered in Wilmette, Illinois.

MNPR Stock Price History

MNPR Stock News Headlines

Monopar Therapeutics Inc (MNPR)
Monopar Therapeutics Inc
Dow Surges Over 150 Points; AerCap Posts Upbeat Earnings
See More Headlines
Receive MNPR Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Monopar Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
3/28/2024
Today
5/23/2024
Next Earnings (Estimated)
8/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:MNPR
Fax
N/A
Employees
9
Year Founded
2014

Price Target and Rating

Average Stock Price Target
$2.00
High Stock Price Target
$2.00
Low Stock Price Target
$2.00
Potential Upside/Downside
+222.6%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-8,400,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.43 per share

Miscellaneous

Free Float
10,211,000
Market Cap
$10.84 million
Optionable
Not Optionable
Beta
1.17

Social Links

13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Chandler D. Robinson M.B.A. (Age 40)
    M.D., M.Sc., MBA, MSc, Co-Founder, CEO, President & Director
    Comp: $710.5k
  • Ms. Kim R. Tsuchimoto CPA (Age 61)
    CFO, Secretary, Treasurer & Director
    Comp: $354k
  • Mr. Andrew J. Cittadine M.B.A. (Age 51)
    Chief Operating Officer
    Comp: $416.7k
  • Dr. Patrice P. Rioux M.D. (Age 73)
    Ph.D., Acting Chief Medical Officer

MNPR Stock Analysis - Frequently Asked Questions

Should I buy or sell Monopar Therapeutics stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Monopar Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MNPR shares.
View MNPR analyst ratings
or view top-rated stocks.

What is Monopar Therapeutics' stock price target for 2024?

2 equities research analysts have issued 12 month price targets for Monopar Therapeutics' shares. Their MNPR share price targets range from $2.00 to $2.00. On average, they anticipate the company's stock price to reach $2.00 in the next year. This suggests a possible upside of 222.6% from the stock's current price.
View analysts price targets for MNPR
or view top-rated stocks among Wall Street analysts.

How have MNPR shares performed in 2024?

Monopar Therapeutics' stock was trading at $0.3402 at the beginning of 2024. Since then, MNPR shares have increased by 82.2% and is now trading at $0.62.
View the best growth stocks for 2024 here
.

When is Monopar Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024.
View our MNPR earnings forecast
.

How were Monopar Therapeutics' earnings last quarter?

Monopar Therapeutics Inc. (NASDAQ:MNPR) posted its quarterly earnings results on Thursday, March, 28th. The company reported ($0.12) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.05.

What other stocks do shareholders of Monopar Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Monopar Therapeutics investors own include Entasis Therapeutics (ETTX), Fulcrum Therapeutics (FULC), Sorrento Therapeutics (SRNE), Akero Therapeutics (AKRO), Chimerix (CMRX), Trevena (TRVN), Aldeyra Therapeutics (ALDX), Advanced Micro Devices (AMD) and Aquestive Therapeutics (AQST).

When did Monopar Therapeutics IPO?

Monopar Therapeutics (MNPR) raised $9 million in an initial public offering (IPO) on Thursday, December 19th 2019. The company issued 1,100,000 shares at a price of $8.00 per share. JonesTrading acted as the underwriter for the IPO and Arcadia Securities was co-manager.

How do I buy shares of Monopar Therapeutics?

Shares of MNPR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Monopar Therapeutics have any subsidiaries?
The following companies are subsidiares of Monopar Therapeutics: Monopar Therapeutics Pty Ltd, and Monopar Therapeutics SARL.
Read More
This page (NASDAQ:MNPR) was last updated on 5/24/2024 by MarketBeat.com Staff

From Our Partners